Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

159 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

Cardiologybreast cancerCardio-Oncology

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

By MedXY|Oct 24, 2025

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

Cardiologycardiovascular outcomesheart failure

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

By MedXY|Oct 10, 2025

Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

Cardiologycardiovascular outcomesheart failure

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY|Oct 10, 2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

Cardiologyheart failureHispanic population

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

By MedXY|Oct 9, 2025

A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prev

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

CardiologyCardiac Magnetic ResonanceCoronary Angiography

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

By MedXY|Oct 9, 2025

A multicenter trial shows cardiac MRI offers comparable sensitivity to invasive coronary angiography for diagnosing ischemic cardiomyopathy, reducing invasive procedures in newly diagnosed heart failure patients.

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

Cardiologyheart failureHFrEF

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

By MedXY|Oct 8, 2025

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo

Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact

Diabetes & Endocrinologyheart failure

Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact

By MedXY|Oct 8, 2025

A prespecified subanalysis of the PACMAN-HF trial demonstrates that individualized nutritional interventions in chronic heart failure patients at risk of malnutrition improve nutritional status and functional capacity but do not significant

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

CardiologyFINEARTS-HFfinerenone

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY|Oct 7, 2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFp

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

Cardiologyatrial fibrillationgeriatric cardiology

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY|Oct 6, 2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

CardiologyDapagliflozinheart failure

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

By MedXY|Oct 6, 2025

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF i

Fontan Circulatory Failure and Heart Transplant Survival: Insights from a Multicenter Retrospective Cohort Study

Cardiologycongenital heart diseaseheart failure

Fontan Circulatory Failure and Heart Transplant Survival: Insights from a Multicenter Retrospective Cohort Study

By MedXY|Oct 6, 2025

This study identifies key Fontan circulatory failure morbidities impacting survival from heart transplant waitlisting through one year post-transplant, highlighting cyanosis and frequent hospitalizations as critical risk factors.

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

Cardiologycardiovascular diseaseheart failure

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

By MedXY|Oct 6, 2025

The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

Cardiologyclinical trialheart failure

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

By MedXY|Oct 6, 2025

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

Cardiologyheart failureT1 mapping

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

By MedXY|Oct 6, 2025

Cardiac MRI T1 mapping and extracellular volume fraction (ECV) provide noninvasive markers of myocardial fibrosis, showing consistent prognostic value across heart failure subtypes and non-ischaemic dilated cardiomyopathy for adverse cardio

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

Cardiologyatrial fibrillationheart failure

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

By MedXY|Oct 6, 2025

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

CardiologyE/A ratioheart failure

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

By MedXY|Oct 6, 2025

Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

CardiologyE/A ratioheart failure

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

By MedXY|Oct 6, 2025

This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and the

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

AIheart failure

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

By MedXY|Oct 6, 2025

Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

Cardiologyheart failureHFpEF

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY|Oct 5, 2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

Cardiologycardiac glycosidesclinical trial

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

By MedXY|Oct 5, 2025

The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Prev 1 5 6 7 8 Next

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities